Drug Approval | January 03, 2024
Alembic Pharmaceuticals received 8 USFDA approvals in Q3FY24
The company has received five final approvals
The company has received five final approvals
Ribo's cutting edge RIBO-GalSTAR platform enables the development of RNAi therapeutics targeting disease-causing genes specifically in hepatocytes
The company has received marketing authorisation for docetaxel from Israel and cytarabine from Colombia
The commissioning of the facility represents the culmination of a £45m investment to address rapidly growing demand for ADC manufacturing, supported by a £2.4m Scottish Enterprise grant
ABDM Microsites Mobile Application for field officers and ABDM Microsites Dashboard launched for effective on-ground implementation and monitoring
Studies have demonstrated that ZYIL1 is highly potent and can suppress inflammation caused by NLRP3 inflammasome activation
Expansion of presence in India with electrical safety, electromagnetic compatibility and medical device biocompatibility, toxicity and microbiology testing and certification services
The findings of Phase 3 study are in line with Phase 2 study conducted in the US and Europe
Late-stage Fabhalta development program ongoing in multiple complement-mediated conditions
The esteemed duo perfectly embody the brand's core values of family, love, and the special bond we share with our pets
Subscribe To Our Newsletter & Stay Updated
